Himanshu Mishra, Microbiologist at Zydus Lifescience, shared a post on LinkedIn:
“In situ extended immune activation immediately after tumor resection by oncolytic virus controls postoperative tumor recurrence
• Postoperative tumor recurrence remains a major challenge for patients. Oncolytic virus (OV) therapy has attracted increasing attention in recent years. Here, we develop a supramolecular hydrogel that enables the extended release of type V oncolytic adenovirus (Adv), with its stability confirmed experimentally.
• In situ treatment with the Adv-loaded hydrogel (Adv@Nap gel), administered immediately after tumor resection, efficiently activates the type I interferon pathway, induces both innate and adaptive immunity, controls postoperative tumor recurrence and metastasis, and prolongs survival in mice. We further verify the ability of instant in situ treatment with Adv@Nap gel to inhibit postoperative tumor recurrence.
• Notably, oncolytic herpes simplex virus or vaccinia virus loaded in Nap gel also demonstrated the ability to control postoperative tumor recurrence. Thus, hydrogel-loaded OVs capable of inducing extended immune activation represent a paradigm for sustained antitumor immunotherapy. In situ sustained immune activation initiated during surgery may therefore serve as an important and universal treatment guideline.
Highlights:
- A stable hydrogel for sustained release of oncolytic viruses (OVs) was constructed.
- In situ OVs@Nap gel treatment, administered immediately after surgery, controls tumor recurrence.
- Adv@Nap gel treatment induces a robust immune response by activating the type I interferon pathway.
- This strategy demonstrates broad-spectrum applicability across multiple oncolytic virus types.”
Read more posts about Himanshu Mishra on OncoDaily.